Title:
MUCOLYTIC AGENTS FOR USE IN TRETAING PULMONARY SARCOIDOSIS
Document Type and Number:
WIPO Patent Application WO/2016/040169
Kind Code:
A3
Abstract:
Mucolytic agents for use in treating pulmonary sarcoidosis are described herein. Patients in need of treatment for pulmonary sarcoidosis are administered a therapeutically effective amount of a mucolytic agent such as DNase I, Mesna or DiMesna. In some embodiments, the DNase I is a recombinant human DNase I such as dornase alfa.
More Like This:
Inventors:
BURNS BARRY (US)
Application Number:
PCT/US2015/048606
Publication Date:
May 26, 2016
Filing Date:
September 04, 2015
Export Citation:
Assignee:
BURNS BARRY (US)
International Classes:
A61K9/00; A61K31/185; A61K31/198; A61K38/46; A61P11/12
Foreign References:
| EP1004302A2 | 2000-05-31 | |||
| US6348343B2 | 2002-02-19 |
Other References:
DOROTA M. RADOMSKA-LESNIEWSKA ET AL.: "N-acetylcysteine inhibits IL -8 and MMP-9 release and ICAM-1 expression by bronchoalveolar cells from interstitial lung disease patients", PHARMACOLOGICAL REPORTS, vol. 62, no. 1, 1 January 2010 (2010-01-01), pages 131 - 138, XP055257519, ISSN: 1734-1140
TAHANOVICH NATALLIA D. ET AL.: "P3435 The evaluation of oxygen-activating function of mononuclear phagocytes in sarcoidosis", 354 CLINICAL ASPECTS IN THE MANAGEMENT OF SARCOIDOSIS - THEMATIC POSTER SESSION, 7 October 2008 (2008-10-07), pages 596s, XP002755409, Retrieved from the Internet
ANONYMOUS: "NCT01587001 on 2014_05_14 The Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis", CLINICALTRIALS.GOV ARCHIVE, 14 May 2014 (2014-05-14), pages 1 - 3, XP055257542, Retrieved from the Internet [retrieved on 20160311]
BOOTS A W ET AL.: "Antioxidant status associated with inflammation in sarcoidosis: A potential role for antioxidants", RESPIRATORY MEDICINE, BAILLIERE TINDALL, vol. 103, no. 3, 1 March 2009 (2009-03-01), LONDON, GB, pages 364 - 372, XP025907277, ISSN: 0954-6111, [retrieved on 20081117]
GRESSIER B ET AL.: "Comparison of in vitro effects of two thiol-containing drugs on human neutrophils hydrogen peroxide production. - PubMed - NCBI", METHODS FIND EXP CLIN PHARMACOL., 1 January 1993 (1993-01-01), pages 101 - 105, XP055258137, Retrieved from the Internet [retrieved on 20160314]
KARL PAUL ET AL.: "Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients with Cystic Fibrosis", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE., vol. 169, no. 6, 15 March 2004 (2004-03-15), US, pages 719 - 725, XP055257803, ISSN: 1073-449X
TAHANOVICH NATALLIA D. ET AL.: "P3435 The evaluation of oxygen-activating function of mononuclear phagocytes in sarcoidosis", 354 CLINICAL ASPECTS IN THE MANAGEMENT OF SARCOIDOSIS - THEMATIC POSTER SESSION, 7 October 2008 (2008-10-07), pages 596s, XP002755409, Retrieved from the Internet
ANONYMOUS: "NCT01587001 on 2014_05_14 The Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis", CLINICALTRIALS.GOV ARCHIVE, 14 May 2014 (2014-05-14), pages 1 - 3, XP055257542, Retrieved from the Internet
BOOTS A W ET AL.: "Antioxidant status associated with inflammation in sarcoidosis: A potential role for antioxidants", RESPIRATORY MEDICINE, BAILLIERE TINDALL, vol. 103, no. 3, 1 March 2009 (2009-03-01), LONDON, GB, pages 364 - 372, XP025907277, ISSN: 0954-6111, [retrieved on 20081117]
GRESSIER B ET AL.: "Comparison of in vitro effects of two thiol-containing drugs on human neutrophils hydrogen peroxide production. - PubMed - NCBI", METHODS FIND EXP CLIN PHARMACOL., 1 January 1993 (1993-01-01), pages 101 - 105, XP055258137, Retrieved from the Internet
KARL PAUL ET AL.: "Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients with Cystic Fibrosis", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE., vol. 169, no. 6, 15 March 2004 (2004-03-15), US, pages 719 - 725, XP055257803, ISSN: 1073-449X
Attorney, Agent or Firm:
BIRDE, Patrick J. et al. (One BroadwayNew York, NY, US)
Download PDF: